Senti Biosciences, Inc. Files 2023 Annual Report on Form 10-K

Ticker: SNTI · Form: 10-K · Filed: Mar 21, 2024 · CIK: 1854270

Sentiment: neutral

Topics: 10-K, Annual Report, Senti Biosciences, Biotechnology, Financials

TL;DR

<b>Senti Biosciences, Inc. has filed its 2023 10-K report, detailing its financial performance and business operations.</b>

AI Summary

Senti Biosciences, Inc. (SNTI) filed a Annual Report (10-K) with the SEC on March 21, 2024. Senti Biosciences, Inc. filed its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and operates in the Biological Products sector. Its principal business address is 2 Corporate Drive, First Floor, South San Francisco, CA 94080. The filing includes financial data for the fiscal years 2023 and 2022. The report is submitted under the Securities Exchange Act of 1934.

Why It Matters

For investors and stakeholders tracking Senti Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Senti Biosciences' financial health and operational status for the fiscal year 2023, crucial for investors to assess the company's performance and future prospects. The detailed financial statements and risk factors within the report are essential for understanding the company's current market position and potential challenges in the biotechnology sector.

Risk Assessment

Risk Level: — Senti Biosciences, Inc. shows moderate risk based on this filing. The company's financial performance and operational status are detailed in this 10-K filing, which is standard for public companies but does not inherently indicate positive or negative trends without further analysis of the specific financial figures and business developments.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to assess Senti Biosciences' financial health and strategic direction.

Key Numbers

Key Players & Entities

FAQ

When did Senti Biosciences, Inc. file this 10-K?

Senti Biosciences, Inc. filed this Annual Report (10-K) with the SEC on March 21, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Senti Biosciences, Inc. (SNTI).

Where can I read the original 10-K filing from Senti Biosciences, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Senti Biosciences, Inc..

What are the key takeaways from Senti Biosciences, Inc.'s 10-K?

Senti Biosciences, Inc. filed this 10-K on March 21, 2024. Key takeaways: Senti Biosciences, Inc. filed its annual report for the fiscal year ended December 31, 2023.. The company is incorporated in Delaware and operates in the Biological Products sector.. Its principal business address is 2 Corporate Drive, First Floor, South San Francisco, CA 94080..

Is Senti Biosciences, Inc. a risky investment based on this filing?

Based on this 10-K, Senti Biosciences, Inc. presents a moderate-risk profile. The company's financial performance and operational status are detailed in this 10-K filing, which is standard for public companies but does not inherently indicate positive or negative trends without further analysis of the specific financial figures and business developments.

What should investors do after reading Senti Biosciences, Inc.'s 10-K?

Review the detailed financial statements and risk factors in the 10-K to assess Senti Biosciences' financial health and strategic direction. The overall sentiment from this filing is neutral.

How does Senti Biosciences, Inc. compare to its industry peers?

Senti Biosciences operates within the biotechnology industry, specifically focusing on biological products.

Are there regulatory concerns for Senti Biosciences, Inc.?

The filing is made in accordance with the Securities Exchange Act of 1934, a standard regulatory requirement for public companies in the United States.

Industry Context

Senti Biosciences operates within the biotechnology industry, specifically focusing on biological products.

Regulatory Implications

The filing is made in accordance with the Securities Exchange Act of 1934, a standard regulatory requirement for public companies in the United States.

What Investors Should Do

  1. Analyze the financial statements for revenue, net income, and cash flow for fiscal years 2023 and 2022.
  2. Review the risk factors section to identify potential challenges and uncertainties facing the company.
  3. Examine any disclosed executive compensation details to understand management incentives.

Key Dates

Year-Over-Year Comparison

This is the initial 10-K filing for Senti Biosciences, Inc. for the fiscal year ending December 31, 2023, as indicated by the absence of prior year comparative data within the provided snippet.

Filing Stats: 4,387 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-03-21 16:53:39

Key Financial Figures

Filing Documents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS 3 PART I

Risk Factors

Item 1A. Risk Factors 45

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 120 Item 1C. Cybersecurity 120

Properties

Item 2. Properties 121

Legal Proceedings

Item 3. Legal Proceedings 121

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 121 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 122

[RESERVED]

Item 6. [RESERVED] 122

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 122

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 137

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 137

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 183

Controls and Procedures

Item 9A. Controls and Procedures 183

Other Information

Item 9B. Other Information 184

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 184 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 185

Executive Compensation

Item 11. Executive Compensation 185

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 185

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 185

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 185 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 186

Form 10-K Summary

Item 16. Form 10-K Summary 191

SIGNATURES

SIGNATURES 192 2 Table of Contents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report" or "Form 10-K") and some of the information incorporated by reference, includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of Senti Biosciences, Inc. ("Senti" or the "Company"). These statements are based on the beliefs and assumptions of the management of Senti. Although Senti believes that their respective plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot assure you that it will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes", "estimates", "expects", "projects", "forecasts", "may", "might", "will", "should", "seeks", "plans", "scheduled", "possible", "anticipates", "intends", "aims", "works", "focuses", "aspires", "strives" or "sets out" or similar expressions. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements which speak only as of the date hereof. Forward-looking statements contained in this Annual Report include, for example, statements about: the accuracy of our estimates and projections of financial information, including expenses, capital requirements, cash utilization and runway, need for additional financing and market opportunities; our ability to maintain the listing of our common stock on Nasdaq, and the potential liqu

Business

Item 1. Business Unless the context otherwise requires, for purposes of this section, the terms "we," "us," "our," "our Company," "the Company" or "Senti" refer to Senti Biosciences, Inc. and its subsidiaries. Overview We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. We are applying our gene circuit technologies to develop a pipeline of medicines that use off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") cells with the goal of addressing major challenges and providing potentially lifesaving treatments for people living with cancer. Our lead product candidates utilize off-the-shelf healthy adult donor derived NK cells to create CAR-NK cells outfitted with Gene Circuit technologies in several oncology indications with high unmet need. We expect to initiate clinical trials of two of our product candidates in 2024. Our lead product candidate SENTI-202, a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of acute myeloid leukemia ("AML"), received clearance of its Investigational New Drug application ("IND") by the U.S. F

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing